Ken Borow is a distinguished Harvard-trained cardiologist, internist, and pediatrician with over 100 publications and extensive experience in clinical research, drug development, and biopharma consulting. Dr. Borow has served as president and CEO of Encorium Group, Inc. and Borow Consulting Group, LLC where he designed and conducted multiple large clinical trials including Pfizer's REVERSAL and CAMELOT studies. Apart from his extensive industry experience, Dr. Borow has been an assistant professor of medicine and pediatrics at Harvard Medical School, a professor of medicine and pediatrics at the University of Chicago, and a senior member of the NHLBI Task Force on Heart Failure. In his current role as president and CMO of MediMergent, LLC, Dr. Borow is spearheading a pioneering approach to integrating clinical data from EMRs and patient feedback for assessments of safety, clinical outcomes, and comparative effectiveness.